Stratagraft skin substitute is well-tolerated and is not acutely immunogenic in patients with traumatic wounds: Results from a prospective, randomized, controlled dose escalation trial

Annals of Surgery

Volumn 253, Issue 4, 2011, Pages 672-683

  Centanni, John M ^a   Straseski, Joely A ^b   Wicks, April ^a   Hank, Jacquelyn A ^c   Rasmussen, Cathy A ^a,b   Lokuta, Mary A ^a   Schurr, Michael J ^c   Foster, Kevin N ^d   Faucher, Lee D ^c   Caruso, Daniel M ^d   Comer, Allen R ^a   Allen Hoffmann, B Lynn ^a,b,e  

^a Stratatech Corporation   (United States)

^b Laboratory Medicine   (United States)

^c UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^d MARICOPA MEDICAL CENTER   (United States)

^e UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CHROMIUM;

ALLOGRAFT; ANTIGENICITY; ARTICLE; AUTOGRAFT; B LYMPHOCYTE; CADAVER; CELL COMPOSITION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOLYSIS; FULL THICKNESS SKIN GRAFT; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOFLUORESCENCE; IMMUNOGENICITY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; KERATINOCYTE; LANGERHANS CELL; LYMPHOCYTE PROLIFERATION; MULTICENTER STUDY; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; STRATAGRAFT SKIN SUBSTITUTE; T LYMPHOCYTE; TISSUE STRUCTURE; WOUND;

ADULT; AGED; CADAVER; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; INJURY SEVERITY SCORE; KERATINOCYTES; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PROSPECTIVE STUDIES; SKIN; SKIN TRANSPLANTATION; SKIN, ARTIFICIAL; SOFT TISSUE INJURIES; TRANSPLANTATION IMMUNOLOGY; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS; WOUND HEALING;

EID: 79953164897     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e318210f3bd     Document Type: Article

References (70)

1. Rheinwald JG, Green H. Serial cultivation of strains of human epidermal keratinocytes: the formation of keratinizing colonies from single cells. Cell. 1975;6(3):331-343.
2. Barrandon Y, Green H. Three clonal types of keratinocyte with different capacities for multiplication. Proc Natl Acad Sci USA. 1987;84(8):2302-2306. (Pubitemid 17075859)
3. Allen-Hoffmann BL, Schlosser SJ, Ivarie CA, et al. Normal growth and differentiation in a spontaneously immortalized near-diploid human keratinocyte cell line, NIKS. J Invest Dermatol. 2000;114(3):444-455. (Pubitemid 30415329)
4. Hrabchak C, Flynn L, Woodhouse KA. Biological skin substitutes for wound cover and closure. Expert Rev Med Devices. 2006;3(3):373-385.
5. Ehrenreich M, Ruszczak Z. Update on tissue-engineered biological dressings. Tissue Eng. 2006;12(9):2407-2424. (Pubitemid 46150659)
6. Eisenbud D, Huang N, Luke S, et al. Skin substitutes and wound healing: current status and challenges. Wounds. 2004;16(1):2-17. (Pubitemid 38253195)
7. MacNeil S. Progress and opportunities for tissue-engineered skin. Nature. 2007;445(7130):874-880.
8. Passeron T, Coelho SG, Miyamura Y, et al. Immunohistochemistry and in situ hybridization in the study of human skin melanocytes. Exp Dermatol. 2007;16(3):162-170. (Pubitemid 46242957)
9. From somatic cells to pluripotent stem cells. BioProbes. 2010;62:13-15.
10. Daar AS, Fuggle SV, Fabre JW, et al. The detailed distribution of MHC Class II antigens in normal human organs. Transplantation. 1984;38(3):293-298. (Pubitemid 14035182)
11. Wikner NE, Huff JC, Norris DA, et al. Study of HLA-DR synthesis in cultured human keratinocytes. J Invest Dermatol. 1986;87(5):559-564. (Pubitemid 17178880)
12. Morhenn VB, Benike CJ, Cox AJ, et al. Cultured human epidermal cells do not synthesize HLA-DR. J Invest Dermatol. 1982;78(1):32-37. (Pubitemid 12207152)
13. Barnstable CJ, Jones EA, Crumpton MJ. Isolation, structure and genetics of HLA-A, -B, -C and -DRw (Ia) antigens. Br Med Bull. 1978;34(3):241-246. (Pubitemid 9012638)
14. Daar AS, Fuggle SV, Fabre JW, et al. The detailed distribution of HLA-A, B, C antigens in normal human organs. Transplantation. 1984;38(3):287-292. (Pubitemid 14035181)
15. Dausset J, Contu L, Legrand L, et al. The role of HLA-DR antigens in transplantation-survival of skin allografts in HLA-haploidentical donorrecipient combinations. Transplant Proc. 1978;10(4):995-999. (Pubitemid 9113878)
16. Jonker M, Hoogeboom J, van Leeuwen A, et al. Influence of matching for HLA-DR antigens on skin graft survival. Transplantation. 1979;27(2):91-94. (Pubitemid 9191664)
17. Stingl G, Tamaki K, Katz SI. Origin and function of epidermal Langerhans cells. Immunol Rev. 1980;53:149-174. (Pubitemid 11119137)
18. Teunissen MB. Dynamic nature and function of epidermal Langerhans cells in vivo and in vitro: a review, with emphasis on human Langerhans cells. Histochem J. 1992;24(10):697-716.
19. Klareskog L, Tjernlund U, Forsum U, et al. Epidermal Langerhans cells express Ia antigens. Nature. 1977;268(5617):248-250. (Pubitemid 8139186)
20. Rowden G, LewisMG, Sullivan AK. Ia antigen expression on human epidermal Langerhans cells. Nature. 1977;268(5617):247-248. (Pubitemid 8139185)
21. Schurr MJ, Foster KN, Centanni JM, et al. Phase I/II clinical evaluation of StrataGraft: a consistent, pathogen-free human skin substitute. J Trauma-Inj Infect Crit Care. 2009;66(3):866-873.
22. Okah FA, Wickett RR, Pickens WL, et al. Surface electrical capacitance as a noninvasive bedside measure of epidermal barrier maturation in the newborn infant. Pediatrics. 1995;96(4, Pt 1):688-692.
23. Boyce ST, Supp AP, Harriger MD, et al. Surface electrical capacitance as a noninvasive index of epidermal barrier in cultured skin substitutes in athymic mice. J Invest Dermatol. 1996;107(1):82-87. (Pubitemid 26236099)
24. Gerdes J, Lemke H, Baisch H, et al. Cell cycle analysis of a cell proliferationassociated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol. 1984;133(4):1710-1715. (Pubitemid 14035254)
25. Patel GK, Wilson CH, Harding KG, et al. Numerous keratinocyte subtypes involved in wound re-epithelialization. J Invest Dermatol. 2006;126(2):497-502. (Pubitemid 43323188)
26. Uchi H, Terao H, Koga T, et al. Cytokines and chemokines in the epidermis. J Dermatol Sci. 2000;24(suppl 1):S29-S38. (Pubitemid 32008458)
27. Nickoloff BJ, Turka LA. Immunological functions of non-professional antigenpresenting cells: new insights from studies of T-cell interactions with keratinocytes. Immunol Today. 1994;15(10):464-469. (Pubitemid 24316011)
28. Mutlu S, Matthews JB, Midda M, et al.MHC antigen expression in human oral squamous carcinoma cell lines. J Pathol. 1991;165(2):129-136.
29. Basham TY, Nickoloff BJ, Merigan TC, et al. Recombinant gamma interferon induces HLA-DR expression on cultured human keratinocytes. J Invest Dermatol. 1984;83(2):88-90. (Pubitemid 14054909)
30. Denfeld RW, Hollenbaugh D, Fehrenbach A, et al. CD40 is functionally expressed on human keratinocytes. Eur J Immunol. 1996;26(10):2329-2334. (Pubitemid 26340931)
31. Basham TY, Nickoloff BJ, Merigan TC, et al. Recombinant gamma interferon differentially regulates class II antigen expression and biosynthesis on cultured normal human keratinocytes. J Interferon Res. 1985;5(1):23-32. (Pubitemid 15086866)
32. Volc-Platzer B, Leibl H, Luger T, et al. Human epidermal cells synthesize HLA-DR alloantigens in vitro upon stimulation with gamma-interferon. J Invest Dermatol. 1985;85(1):16-19. (Pubitemid 15069706)
33. Peguet-Navarro J, Dalbiez-Gauthier C, Moulon C, et al. CD40 ligation of human keratinocytes inhibits their proliferation and induces their differentiation. J Immunol. 1997;158(1):144-152. (Pubitemid 127483851)
34. SkoskiewiczMJ, Colvin RB, Schneeberger EE, et al.Widespread and selective induction of major histocompatibility complex-determined antigens in vivo by gamma interferon. J ExpMed. 1985;162(5):1645-1664. (Pubitemid 16195365)
35. RossW, Hall PA. Ki67: from antibody to molecule to understanding? Clin Mol Pathol. 1995;48(3):M113-M117.
36. Camidge DR, Davies MJ, Laud PJ, et al. Factors determining the optimal body site and method for obtaining punch biopsies of human skin as a tissue in which to assess pharmacodynamic and pharmacokinetic endpoints in drug development studies. Cancer Chemother Pharmacol. 2006;57(1):52-58.
37. Gilhar A, Ullmann Y, Karry R, et al. Aging of human epidermis: reversal of aging changes correlates with reversal of keratinocyte fas expression and apoptosis. J Gerontol A Biol Sci Med Sci. 2004;59(5):411-415. (Pubitemid 38649930)
38. Solari MG, Thomson AW. Human dendritic cells and transplant outcome. Transplantation. 2008;85(11):1513-1522.
39. Obhrai JS, Oberbarnscheidt M, Zhang N, et al. Langerhans cells are not required for efficient skin graft rejection. J Invest Dermatol. 2008;128(8):1950-1955. (Pubitemid 352001229)
40. Lafferty KJ, Prowse SJ, Simeonovic CJ, et al. Immunobiology of tissue transplantation: a return to the passenger leukocyte concept. Annu Rev Immunol. 1983;1:143-173.
41. Bowen KM, Lafferty KJ. Reversal of diabetes by allogenic islet transplantation without immunosuppression. Aust J Exp Biol Med Sci. 1980;58(5):441-447. (Pubitemid 11082903)
42. Caballero A, Fernandez N, Lavado R, et al. Tolerogenic response: allorecognition pathways. Transpl Immunol. 2006;17(1):3-6. (Pubitemid 44828808)
43. Game DS, Lechler RI. Pathways of allorecognition: implications for transplantation tolerance. Transpl Immunol. 2002;10(2-3):101-108.
44. Lafferty KJ, Bootes A, Dart G, et al. Effect of organ culture on the survival of thyroid allografts in mice. Transplantation. 1976;22(2):138-149.
45. Jacobs BB. Ovarian allograft survival. Prolongation after passage in vitro. Transplantation. 1974;18(5):454-457.
46. Lueker DC, Sharpton TR. Survival of ovarian allografts following maintenance in organ culture. Transplantation. 1974;18(5):457-458.
47. Laning JC, DeLuca JE, Hardin-Young J. Effects of immunoregulatory cytokines on the immunogenic potential of the cellular components of a bilayered living skin equivalent. Tissue Eng. 1999;5(2):171-181. (Pubitemid 29196558)
48. DaynesRA,EmamM, Krueger GG, et al. Expression of Ia antigen on epidermal keratinocytes after the grafting of normal skin to nude mice. J Immunol. 1983;130(4):1536-1539. (Pubitemid 13091590)
49. Krueger GG, Daynes RA, Roberts LK, et al. Migration of Langerhans cells and the expression of Ia on epidermal cells following the grafting of normal skin to nude mice. Exp Cell Biol. 1984;52(1-2):97-102. (Pubitemid 14156200)
50. Laning JC, DeLuca JE, Isaacs CM, et al. In vitro analysis of CD40-CD154 and CD28-CD80/86 interactions in the primary T-cell response to allogeneic "nonprofessional" antigen presenting cells. Transplantation. 2001;71(10):1467-1474. (Pubitemid 32507123)
51. Nickoloff BJ, Basham TY,Merigan TC, et al. Human keratinocyte-lymphocyte reactions in vitro. J Invest Dermatol. 1986;87(1):11-18. (Pubitemid 16090868)
52. Ledbetter JA, Imboden JB, Schieven GL, et al. CD28 ligation in T-cell activation: evidence for two signal transduction pathways. Blood. 1990;75(7):1531-1539. (Pubitemid 20114894)
53. Muhart M, McFalls S, Kirsner R, et al. Bioengineered skin. Lancet. 1997;350(9085):1142.
54. Falanga V, Margolis D, Alvarez O, et al. Rapid healing of venous ulcers and lack of clinical rejection with an allogeneic cultured human skin equivalent. Human Skin Equivalent Investigators Group. Arch Dermatol. 1998;134(3): 293-300. (Pubitemid 28141616)
55. EaglsteinWH, Iriondo M, Laszlo K.Acomposite skin substitute (graftskin) for surgical wounds. A clinical experience. Dermatol Surg. 1995;21(10):839-843.
56. Volc-Platzer B, Majdic O, Knapp W, et al. Evidence of HLA-DR antigen biosynthesis by human keratinocytes in disease. J Exp Med. 1984;159(6):1784- 1789. (Pubitemid 14117084)
57. Aubock J, Romani N, Grubauer G, et al. HLA-DR expression on keratinocytes is a common feature of diseased skin. Br J Dermatol. 1986;114(4):465-472. (Pubitemid 16101427)
58. Griffiths M, Livingstone R, Price R, et al. Survival of Apligraf in acute human wounds. Tissue Engineering. 2004;10(7/8):1180-1195. (Pubitemid 39223796)
59. EaglsteinWH, Alvarez OM, Auletta M, et al. Acute excisional wounds treated with a tissue-engineered skin (Apligraf). Dermatol Surg. 1999;25(3):195-201. (Pubitemid 29146985)
60. Phillips TJ, Manzoor J, Rojas A, et al. The longevity of a bilayered skin substitute after application to venous ulcers. Arch Dermatol. 2002;138(8):1079-1081. (Pubitemid 34875612)
61. Hu S, Kirsner RS, Falanga V, et al. Evaluation of Apligraf persistence and basement membrane restoration in donor site wounds: a pilot study. Wound Repair Regen. 2006;14(4):427-433. (Pubitemid 44266599)
62. Piontek GE, Taniguchi K, Ljunggren HG, et al. YAC-1 MHC class I variants reveal an association between decreased NK sensitivity and increased H-2 expression after interferon treatment or in vivo passage. J Immunol. 1985;135(6):4281-4288. (Pubitemid 16250426)
63. Harel-Bellan A, Quillet A, Marchiol C, et al. Natural killer susceptibility of human cells may be regulated by genes in the HLA region on chromosome 6. Proc Natl Acad Sci USA. 1986;83(15):5688-5692. (Pubitemid 16001282)
64. Quillet A, Presse F, Marchiol-Fournigault C, et al. Increased resistance to non-MHC-restricted cytotoxicity related to HLA A, B expression. Direct demonstration using beta 2-microglobulin-transfected Daudi cells. J Immunol. 1988;141(1):17-20.
65. Storkus WJ, Howell DN, Salter RD, et al. NK susceptibility varies inversely with target cell class IHLAantigen expression. J Immunol. 1987;138(6):1657-1659. (Pubitemid 17040782)
66. Karlhofer FM, Ribaudo RK, Yokoyama WM. MHC class I alloantigen speci- ficity of Ly-49+ IL-2-activated natural killer cells. Nature. 1992;358(6381): 66-70.
67. Ljunggren HG, Karre K. In search of the 'missing self': MHC molecules and NK cell recognition. Immunol Today. 1990;11(7):237-244. (Pubitemid 20198988)
68. Theobald VA, Lauer JD, Kaplan FA, et al. "Neutral allografts"-lack of allogeneic stimulation by cultured human cells expressing MHC class I and class II antigens. Transplantation. 1993;55(1):128-133. (Pubitemid 23033958)
69. Thivolet J, FaureM, Demidem A, et al. Long-term survival and immunological tolerance of human epidermal allografts produced in culture. Transplantation. 1986;42(3):274-280. (Pubitemid 16020751)
70. Rothermel AL, Wang Y, Schechner J, et al. Endothelial cells present antigens in vivo. BMC Immunol. 2004;5(1):5.